

*Hong Kong Stock Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



開拓藥業有限公司 \*

**KINTOR PHARMACEUTICAL LIMITED**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 9939)**

**VOLUNTARY ANNOUNCEMENT**

**SHARE PURCHASES BY CHAIRMAN OF THE BOARD, EXECUTIVE  
DIRECTOR AND CHIEF EXECUTIVE OFFICER**

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) to update its shareholders and potential investors on the latest development related to the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that Dr. Youzhi Tong (“**Dr. TONG**”, chairman of the Board, executive Director and chief executive officer of the Company) has, through his wholly-owned company KT International Investment Limited, purchased a total of 995,500 shares of the Company in the open market for an aggregate consideration of HK\$1,026,500 (average transaction price was HK\$1.0311 per share) with his own funds on 19 July 2024, 24 July 2024 and 25 July 2024, respectively (the “**Share Purchase**”), representing approximately 0.2225% of the total issued share capital of the Company as at the date of this announcement. Based on the publicly available information to the Company and as far as the Board is aware, the Company still satisfies the requirement of maintaining a sufficient public float after the Share Purchase.

The Board considers that Dr. TONG’s Share Purchase indicates his unswerving confidence in the commercialization prospects and the growth potential of the Company, and the full recognition of the Company’s long-term investment value. The Group will continuously focus on the field of dermatology, cultivate its existing cosmetics products, expand the usage scenarios of the products, and expedite the launch of new cosmetics products including but not limited to 826 acne cream and 939 whitening essence, to further enrich the Group’s product matrix. The Group expects to have seven

cosmetic product types covering anti-hair loss, acne treatment and skin whitening within the year, meeting the varied consumption demands of different consumer groups. Meanwhile, the Group will accelerate its overseas markets expansion of cosmetics products and explore the development potential of key regions as Japan, Europe and Australia, to continuously broaden its market layout and build a global marketing network, enhancing the brand influence and recognition.

**Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** Apart from the cosmetic product of 826 topical anti-hair loss solution, there is no assurance that other products of KX-826 will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board  
**KINTOR PHARMACEUTICAL LIMITED**  
**Dr. Youzhi Tong**  
*Chairman of the Board, Executive Director and  
Chief Executive Officer*

Hong Kong, 29 July 2024

*As at the date of this announcement, the executive Directors are Dr. Youzhi Tong and Dr. Xiang Ni; the non-executive Directors are Mr. Weipeng Gao and Ms. Geqi Wei; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.*

*\* For identification purpose only*